Drug Trial Radar · NCT05162586
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
456
Actual
Start
Mar 31, 2022
Primary completion
Nov 20, 2024
Study completion Nov 20, 2024
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus \[SCLE\] and/or discoid lupus erythematosus \[DLE\]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks Enpatoran is not available through an expanded access program.
Conditions
- Systemic Lupus Erythematosus
Interventions
Enpatoran low doseDrug
Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
Enpatoran medium doseDrug
Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
Enpatoran high doseDrug
Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
PlaceboDrug
Participants will receive placebo matched to Enpatoran up to 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16Time frame: Baseline, week 16
- Cohort B: Number of Participants With British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 24Time frame: At Week 24
Locations
153 sites in 22 countries. Site status is shown where the registry gives one.
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California
Bay Area Arthritis and Osteoporosis
Brandon, Florida
Advance Medical Research Center
Miami, Florida
New Horizon Research Center, Inc
Miami, Florida
Charisma Medical and Research Center
Miami Lakes, Florida
HMD Research, LLC
Orlando, Florida
D&H Tamarac Research Center, LLC
Tamarac, Florida
RNA America Health Sciences
Sugar Hill, Georgia
Dawes Fretzin Dermatology Group, LLC
Indianapolis, Indiana
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan
University of Minnesota
Minneapolis, Minnesota
Across the Life Span
Smithfield, North Carolina
Ohio State University - CTMO Parent
Columbus, Ohio
Ramesh C Gupta, MD - Memphis, TN
Memphis, Tennessee
CINME - Centro De Investigaciones Metabolicas
Buenos Aires, Argentina
Buenos Aires Skin
Ciudad Autonoma Buenos Aires, Argentina
Centro Dermatologico Schejtman
Ciudad Autonoma Buenos Aires, Argentina
Hospital Militar Central Dr. Cosme Argerich
Ciudad Autonoma Buenos Aires, Argentina
Centro de Investigaciones Medicas Mar del Plata - CIM
Mar del Plata, Argentina
Instituto de Reumatologia
Mendoza, Argentina
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Argentina
Instituto Medico de alta Complejidad San Isidro S.A (IMAC)
San Fernando, Argentina
CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
San Juan, Argentina
PSORIAHUE-Medicina Interdisciplinar
San Miguel, Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina
Investigaciones Clinicas Tucuman
San Miguel de Tucumán, Argentina
Monash Medical Centre Clayton
Clayton, Australia
Westmead Hospital - SUPERSEDED
Westmead, Australia
Veracity Clinical Research
Woolloongabba, Australia
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Brazil
Oncovida - Centro de Onco-Hematologia de Mato Grosso
Cuiabá, Brazil
CETI - Centro de Estudos em Terapias Inovadoras Ltda.
Curitiba, Brazil
HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
Fortaleza, Brazil
CMiP - Centro Mineiro de Pesquisa
Juiz de Fora, Brazil
Hospital Bruno Born
Lajeado, Brazil
Hospital Moinhos de Vento
Porto Alegre, Brazil
Clínica SER da Bahia
Salvador, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto - CIP - Centro Integrado de Pesquisa
São José do Rio Preto, Brazil
CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
São Paulo, Brazil
CPCLIN - Centro de Pesquisas Clínicas Ltda.
São Paulo, Brazil
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.